Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases.

Literature DB >> 19756367

Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases.

Tibor Kovács¹, Marianna Farsang, Edina Vitaszil, Péter Barsi, Tamás Györke, Imre Szirmai, Anita Kamondi.

Abstract

Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19756367 DOI： 10.1007/s00702-009-0301-2

Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575

27 in total

1. Amelioration of spinal myoclonus with levetiracetam.

Authors: S C Keswani; E H Kossoff; G L Krauss; C Hagerty
Journal: J Neurol Neurosurg Psychiatry Date: 2002-10 Impact factor: 10.154

2. Cortical-basal ganglionic degeneration.

Authors: D E Riley; A E Lang; A Lewis; L Resch; P Ashby; O Hornykiewicz; S Black
Journal: Neurology Date: 1990-08 Impact factor: 9.910

3. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.

Authors: Roy G Beran; Samuel F Berkovic; Andrew B Black; Gytis Danta; Reinhard Hiersemenzel; Graham J Schapel; Frank J E Vajda
Journal: Epilepsy Res Date: 2005-01-06 Impact factor: 3.045

Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases.

1. Amelioration of spinal myoclonus with levetiracetam.

2. Cortical-basal ganglionic degeneration.

3. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.

4. Efficacy of levetiracetam in Huntington disease.

5. Levetiracetam in tardive dyskinesia.

6. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs.

7. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.

8. MRI in corticobasal degeneration.

9. Electroencephalographic correlates of myoclonus.

10. Coherence analysis in the myoclonus of corticobasal degeneration.

Review 1. An update and review of the treatment of myoclonus.

2. Progressive Supranuclear Palsy and Corticobasal Degeneration.

3. Diagnosis and treatment of corticobasal degeneration.

Review 4. Physiology-Based Treatment of Myoclonus.

5. Suppression of myoclonus in corticobasal degeneration by levetiracetam.

6. Myoclonus in older Cavalier King Charles Spaniels.